Meeting
2022 ASCO Genitourinary Cancers Symposium
Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Heidi Fettke
Peter MacCallum Cancer Center, Melbourne, VIC, Australia
Heidi Fettke , Christine Hauser , Edmond Michael Kwan , Chao Dai , Tiantian Zheng , Amy Wang , Winston Tan , Pan Du , Nicole Ng , Patricia Bukczynska , Siavash Foroughi , Lisa-Jane K. Graham , Lisa Horvath , Kate Lynette Mahon , Shidong Jia , Manish Kohli , Arun Azad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 153)
DOI
10.1200/JCO.2022.40.6_suppl.153
Abstract #
153
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2023 ASCO Genitourinary Cancers Symposium
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
First Author: Channing Judith Paller
Poster
2022 ASCO Genitourinary Cancers Symposium
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
First Author: Channing Judith Paller
Poster
2020 Genitourinary Cancers Symposium
Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).
First Author: Jacob E Berchuck